Fubei Bio is a biopharmaceutical high-tech enterprise dedicated to developing innovative drugs for neurological diseases and developing related cutting-edge technology platforms. Recently, Forbes Biotech completed the Pre-B round of financing exceeding RMB 100 million. This round of financing was led by Dachen Capital, followed by Bloomage Capital, Fangsheng Capital, Zhongguancun Collaborative Innovation Fund and Daoyuan Capital. The old shareholders Gaorong Capital and Qingyuan Capital continued to add support. The funds raised this time will be used for the advancement of clinical projects and the expansion of the preclinical R&D pipeline.
This article is transferred from: https://www.itjuzi.com/investevent/13713102
This site is only for collection, and the copyright belongs to the original author.